JP2023500875A5 - - Google Patents

Info

Publication number
JP2023500875A5
JP2023500875A5 JP2022525715A JP2022525715A JP2023500875A5 JP 2023500875 A5 JP2023500875 A5 JP 2023500875A5 JP 2022525715 A JP2022525715 A JP 2022525715A JP 2022525715 A JP2022525715 A JP 2022525715A JP 2023500875 A5 JP2023500875 A5 JP 2023500875A5
Authority
JP
Japan
Prior art keywords
seq
antibody
cancer
drug conjugate
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022525715A
Other languages
English (en)
Japanese (ja)
Other versions
JP7657213B2 (ja
JP2023500875A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/000917 external-priority patent/WO2021090062A1/en
Publication of JP2023500875A publication Critical patent/JP2023500875A/ja
Publication of JP2023500875A5 publication Critical patent/JP2023500875A5/ja
Application granted granted Critical
Publication of JP7657213B2 publication Critical patent/JP7657213B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022525715A 2019-11-07 2020-11-06 抗メソテリンエリブリン抗体-薬物コンジュゲート及び使用方法 Active JP7657213B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962932373P 2019-11-07 2019-11-07
US62/932,373 2019-11-07
PCT/IB2020/000917 WO2021090062A1 (en) 2019-11-07 2020-11-06 Anti-mesothelin eribulin antibody-drug conjugates and methods of use

Publications (3)

Publication Number Publication Date
JP2023500875A JP2023500875A (ja) 2023-01-11
JP2023500875A5 true JP2023500875A5 (cg-RX-API-DMAC7.html) 2023-11-08
JP7657213B2 JP7657213B2 (ja) 2025-04-04

Family

ID=73943294

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022525715A Active JP7657213B2 (ja) 2019-11-07 2020-11-06 抗メソテリンエリブリン抗体-薬物コンジュゲート及び使用方法

Country Status (17)

Country Link
US (2) US11572414B2 (cg-RX-API-DMAC7.html)
EP (1) EP4055053A1 (cg-RX-API-DMAC7.html)
JP (1) JP7657213B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220095197A (cg-RX-API-DMAC7.html)
CN (1) CN114729042B (cg-RX-API-DMAC7.html)
AU (1) AU2020380603A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022008756A2 (cg-RX-API-DMAC7.html)
CA (1) CA3159541A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022007924A2 (cg-RX-API-DMAC7.html)
IL (1) IL291643A (cg-RX-API-DMAC7.html)
JO (1) JOP20220070A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022005221A (cg-RX-API-DMAC7.html)
MY (1) MY209745A (cg-RX-API-DMAC7.html)
PE (1) PE20230467A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022551036A1 (cg-RX-API-DMAC7.html)
TW (1) TWI877249B (cg-RX-API-DMAC7.html)
WO (1) WO2021090062A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119405833A (zh) 2018-06-01 2025-02-11 卫材R&D管理有限公司 剪接调节抗体-药物缀合物及其使用方法
IL278740B2 (en) 2018-06-01 2024-01-01 Eisai R&D Man Co Ltd Methods for using splicing modulators
CN120189526A (zh) 2018-12-13 2025-06-24 卫材R&D管理有限公司 荷伯希二烯抗体-药物缀合物及使用方法
WO2021090062A1 (en) 2019-11-07 2021-05-14 Eisai R&D Management Co., Ltd. Anti-mesothelin eribulin antibody-drug conjugates and methods of use
EP4161966A1 (en) 2020-06-05 2023-04-12 Eisai R&D Management Co., Ltd. Anti-bcma antibody-drug conjugates and methods of use
MX2024000893A (es) * 2021-07-22 2024-02-06 Shanghai Senhui Medicine Co Ltd Farmaco conjugado de un derivado de eribulina.
EP4385522A1 (en) * 2021-08-13 2024-06-19 Kunshan Xinyunda Biotech Co., Ltd. Microtubule inhibitor-based antibody-drug conjugate
IL311324A (en) * 2021-09-16 2024-05-01 Chia Tai Tianqing Pharmaceutical Group Co Ltd A drug-antibody conjugate against HER3, a preparation including it and its use
TW202321296A (zh) 2021-10-06 2023-06-01 美商鏈接免疫療法公司 抗間皮素抗原結合分子及其用途
CN122349614A (zh) * 2023-10-13 2026-07-07 卫材R&D管理有限公司 抗体-药物缀合物代谢物
WO2026039642A1 (en) * 2024-08-16 2026-02-19 Ardeagen Corporation Anti-mesothelin antibody conjugates and methods of use thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
JPH06507404A (ja) 1991-05-01 1994-08-25 ヘンリー エム.ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン 感染性の呼吸性疾患の治療方法
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5985320A (en) 1996-03-04 1999-11-16 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
DE69732306T2 (de) 1997-01-16 2006-01-12 Massachusetts Institute Of Technology, Cambridge Zubereitung von partikelhaltigen arzneimitteln zur inhalation
CA2632433C (en) 1998-06-17 2012-02-07 Eisai R & D Management Co., Ltd. Methods for preparing macrocyclic analogs and intermediates for preparing same
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
ES2198922T3 (es) 1998-06-24 2004-02-01 Advanced Inhalation Research, Inc. Particulas porosas grandes emitadas por un inhalador.
US9416190B2 (en) * 2012-09-27 2016-08-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin antibodies and methods for eliciting potent antitumor activity
TWI700298B (zh) * 2015-04-13 2020-08-01 美商輝瑞股份有限公司 靶向b細胞成熟抗原之嵌合型抗原受體類
EP3795591B1 (en) 2015-06-19 2023-09-27 Eisai R&D Management Co., Ltd. Cys80 conjugated immunoglobulins
EP4032902A1 (en) 2015-12-18 2022-07-27 Eisai R&D Management Co., Ltd. C-terminal lysine conjugated immunoglobulins
WO2017136769A1 (en) 2016-02-04 2017-08-10 Eisai R&D Management Co., Ltd. Peptide drug conjugates
MY199595A (en) * 2016-03-02 2023-11-08 Eisai R&D Man Co Ltd Eribulin-based antibody-drug conjugates and methods of use
CN119405833A (zh) 2018-06-01 2025-02-11 卫材R&D管理有限公司 剪接调节抗体-药物缀合物及其使用方法
CN120189526A (zh) 2018-12-13 2025-06-24 卫材R&D管理有限公司 荷伯希二烯抗体-药物缀合物及使用方法
WO2021090062A1 (en) 2019-11-07 2021-05-14 Eisai R&D Management Co., Ltd. Anti-mesothelin eribulin antibody-drug conjugates and methods of use
JP7821733B2 (ja) 2020-01-22 2026-02-27 上海森輝医薬有限公司 エリブリン誘導体の薬物複合体、その調製方法及びその医薬的応用
EP4161966A1 (en) 2020-06-05 2023-04-12 Eisai R&D Management Co., Ltd. Anti-bcma antibody-drug conjugates and methods of use

Similar Documents

Publication Publication Date Title
JP2020019787A5 (cg-RX-API-DMAC7.html)
RU2018134331A (ru) Конъюгаты антитело-лекарственное средство на основе эрибулина и способы применения
ES2988698T3 (es) Conjugados de fracciones de unión a la camptotecina
JP6333882B2 (ja) 抗体−薬剤コンジュゲート
RU2483080C2 (ru) Антитела и иммуноконъюгаты и их применение
JP2021532063A5 (cg-RX-API-DMAC7.html)
JP2019535731A5 (cg-RX-API-DMAC7.html)
JP2025183307A5 (cg-RX-API-DMAC7.html)
RU2016117810A (ru) Конъюгаты белок-полимер-лекарственное средство
JP2012522513A5 (cg-RX-API-DMAC7.html)
RU2018119296A (ru) Конъюгаты антитела, содержащие агонисты толл-подобного рецептора
JP2016512832A5 (cg-RX-API-DMAC7.html)
JP2020526584A5 (cg-RX-API-DMAC7.html)
WO2023124963A1 (zh) 一种可逆反应减少的抗体-药物偶联物,其制备方法及应用
CN111295201A (zh) 抗egfr抗体药物结合物(adc)和其用途
JP2022512401A5 (cg-RX-API-DMAC7.html)
JP2022512401A (ja) ハーボキシジエンスプライシング調節薬抗体-薬物コンジュゲート及びその使用方法
JP2020532543A (ja) 抗egfr抗体薬物コンジュゲート(adc)及びその使用
CN117460540A (zh) 艾日布林衍生物的药物偶联物
JPWO2021251459A5 (cg-RX-API-DMAC7.html)
CN105142664A (zh) 投予抗gcc抗体-药物结合物和dna破坏剂来治疗癌症
CN121285392A (zh) 一种抗pdl1抗体-药物偶联物及应用
CN120019074A (zh) 与l1cam结合的新型结合分子
US20260007762A1 (en) Anti-ror2 antibody-drug conjugates
JP2024519585A5 (cg-RX-API-DMAC7.html)